Abstract
Platinum-based anticancer chemotherapy constitutes a cornerstone for the treatment of various solid tumors. However, existing platinum drugs like cisplatin encounter many obstacles such as drug resistance and systemic toxicity in clinical applications. Extensive attempts have been made to minimize the side effects of platinum drugs. This review concentrates on the major development of novel platinum complexes in the last five years, and highlights the complexes with DNA damage mode fundamentally different from that of cisplatin. Diverse platinum complexes are discussed in the text, including analogues of cisplatin or oxaliplatin, monofunctional platinum( II) complexes, polynuclear platinum(II) complexes, trans-platinum(II) complexes, and platinum(IV) complexes. All of these complexes display impressive antitumor activity and some of them show remarkable potentiality to circumvent the resistance to cisplatin. On the basis of these new facts, it can be concluded that structural modifications could substantially modulate the DNA binding mode and DNA damage process, and as a result largely improve the antitumor efficacy of platinum complexes.
Keywords: Antitumor drug, platinum complex, drug design, drug resistance
Anti-Cancer Agents in Medicinal Chemistry
Title: Fresh Platinum Complexes with Promising Antitumor Activity
Volume: 10 Issue: 5
Author(s): Xiaoyong Wang
Affiliation:
Keywords: Antitumor drug, platinum complex, drug design, drug resistance
Abstract: Platinum-based anticancer chemotherapy constitutes a cornerstone for the treatment of various solid tumors. However, existing platinum drugs like cisplatin encounter many obstacles such as drug resistance and systemic toxicity in clinical applications. Extensive attempts have been made to minimize the side effects of platinum drugs. This review concentrates on the major development of novel platinum complexes in the last five years, and highlights the complexes with DNA damage mode fundamentally different from that of cisplatin. Diverse platinum complexes are discussed in the text, including analogues of cisplatin or oxaliplatin, monofunctional platinum( II) complexes, polynuclear platinum(II) complexes, trans-platinum(II) complexes, and platinum(IV) complexes. All of these complexes display impressive antitumor activity and some of them show remarkable potentiality to circumvent the resistance to cisplatin. On the basis of these new facts, it can be concluded that structural modifications could substantially modulate the DNA binding mode and DNA damage process, and as a result largely improve the antitumor efficacy of platinum complexes.
Export Options
About this article
Cite this article as:
Wang Xiaoyong, Fresh Platinum Complexes with Promising Antitumor Activity, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (5) . https://dx.doi.org/10.2174/1871520611009050396
DOI https://dx.doi.org/10.2174/1871520611009050396 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Indazolo[3,2-b]quinazolinones Attack Hepatocellular Carcinoma Hep3B Cells by Inducing Mitochondrial-Dependent Apoptosis and Inhibition of Nrf2/ARE Signaling Pathway
Current Molecular Medicine Anti-Proliferative Compounds for the Prevention of Restenosis: Anti-Restenotic Mechanisms of Paclitaxel Action
Current Pharmaceutical Design Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Albumin Nanocarriers, γ - Irradiated Crosslinked, Combined with Therapeutic Drugs for Cancer Therapy
Current Pharmaceutical Design Precise Analysis of the Autofluorescence Characteristics of Rat Colon Under UVA and Violet Light Excitation
Current Pharmaceutical Biotechnology MicroRNAs: An Apparent Switch for High-Altitude Pulmonary Edema
MicroRNA The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg)
Current Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications
Current Cancer Drug Targets Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick
Mini-Reviews in Medicinal Chemistry Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Toxicity of Carbon Nanotubes
Current Drug Metabolism Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy
Current Cancer Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Cell Survival Signaling in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Editorial [Bioorganic Chemistry Guest Editor: Harri Lonnberg]
Current Organic Chemistry Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Adenosine and the Auditory System
Current Neuropharmacology